SSTR5 Down-Regulates PDX-1 via Inhibition of P38 MAP Kinase

Guisheng Zhou,Shi-He Liu,Xia Lin,Xin-Hua Feng,William E. Fisher,Francis C. Brunicardi
DOI: https://doi.org/10.1016/j.jss.2009.11.443
IF: 2.417
2010-01-01
Journal of Surgical Research
Abstract:Introduction: SSTR5 is one of five somatostatin receptors that mediate the inhibitory effect of somatostatin (SST) on insulin expression/secretion and islet neoplasia, yet the underlying mechanism remains elusive. Pancreatic and duodenal homeobox-1 (PDX-1) is a β-cell-specific transcription factor essential for pancreatic development and maintenance of β-cell functions. The purpose of this study is to determine whether SST/SSTR5 mechanism of action is regulated via PDX-1. Methods: The effect of SSTR5 agonist PRL-1980 on glucagon-like peptide 1 (GLP-1)-stimulated PDX-1 expression was examined by treating β-TC6 insulinoma cells with 0, 2.5, 5, 10 or 20 nM GLP-1 for 12 h with or without 30-min pretreatment of 100 nM PRL-1980, followed by Western blotting of PDX-1. The effect of p38 inhibitor SB202190 on GLP-1-stimulated PDX-1 expression was examined by treating β-TC6 cells with 20 nM GLP-1 for 12 h in the presence or absence of SB202190, followed by Western blotting of PDX-1. Mouse SSTR5 (mSSTR5) shRNA was generated by annealing and ligating the nucleotide 5'-GCCAAGATGAAGACAGTTA-3' from mSSTR5 cDNA into pSUPER vector at BglII and HindIII sites according to a Dharmacon protocol. The effect of SSTR5 knockdown on PDX-1 in MIN6 insulinoma cells was examined by transfecting mSSTR5 shRNA using Lipofectamine 2000, followed by Western blotting of PDX-1, Cyclin E, Cdk4, p53, p21 and p27 using appropriate antibodies. The effect of SSTR5 on PDX-1 in PANC-1 pancreas cancer cells was examined by co-transfecting HA-SSTR5 with Flag-PDX-1 into the cells using Lipofectamine 2000, followed by Western blotting of Flag-PDX-1. Immunoprecipitation/Western blotting was performed in β-TC6 cells treated with GLP-1 to examine the p38-PDX-1 interaction. The serine 61 and 269 residues of PDX-1 were mutated into alanine by performing site-directed mutagenesis. The effect of p38 on these mutants was examined by co-transfecting them with p38 into HEK-293 cells using Lipofectamine 2000, followed by Western blotting of PDX-1. Islet expression of PDX-1, insulin and PCNA in wild-type and SSTR5-/- mice was measured by immunofluorescent staining using appropriate antibodies. Results: 1. SSTR5 agonist inhibited GLP-1-stimulated increase of PDX-1 expression in β-TC6 cells; 2. GLP-1-stimulated PDX-1 expression was accompanied by kinase activation of p38 MAP kinase and p38-specific inhibitor SB202190 blocked GLP-1-stimulated increase of PDX-1 expression in β-TC6 cells; 3. SSTR5 agonist pretreatment inhibited both p38 kinase activation and PDX-1 expression stimulated by GLP-1; 4. Knockdown of SSTR5 by mSSTR5 shRNA enhanced PDX-1 expression in MIN6 cells, which was accompanied by increased expression of Cyclin E and Cdk4 and decreased expression of p53, p21 and p27; 5. co-transfection of SSTR5 with PDX-1 into PANC-1 cells resulted in down-regulation of PDX-1 in a dose-dependent manner; 6. GLP-1 induced an interaction of p38 with PDX-1 in β-TC6 cells; 7. mutation of serine 269 to alanine abolished the stabilizing effect of p38 on PDX-1 in HEK-293 cells; and 8. ablation of SSTR5 resulted in marked islet overexpression of PDX-1 which was accompanied by increased expression of insulin and PCNA in SSTR5-/- mice. Conclusion: These data suggest that p38 stabilizes PDX-1 through regulating its Ser 269 phosphorylation and that SSTR5 inhibits p38 kinase activation and thus down-regulates PDX-1 expression. We conclude that SST/SSTR5 exert their inhibitory effect via down-regulating PDX-1.
What problem does this paper attempt to address?